Supplementation with α-lipoic acid alone or in combination with eicosapentaenoic acid modulates the inflammatory status of healthy overweight or obese women consuming an energy-restricted diet

Journal of Nutrition

Volumn 146, Issue 4, 2016, Pages 889S-896S

  Huerta, Ana E ^a   Prieto Hontoria, Pedro L ^a,d   Sáinz, Neira ^a   Martínez, J Alfredo ^a,b,c   Moreno Aliaga, María J ^a,b,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c IdiSNA Navarra Institute for Health Research   (Spain)

^d Facultad de Estudios del Patrimonio Cultural   (Chile)

Author keywords

Inflammation; Lipoic acid; Nutritional intervention; Obesity; 3 fatty acids

Indexed keywords

ADHESION G PROTEIN COUPLED RECEPTOR E1; ADIPONECTIN; AMYLOID A PROTEIN; APELIN; C REACTIVE PROTEIN; CHEMERIN; G PROTEIN COUPLED RECEPTOR; HAPTOGLOBIN; ICOSAPENTAENOIC ACID; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIOCTIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET RESTRICTION; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DOWN REGULATION; ENERGY CONSUMPTION; FEMALE; GENE EXPRESSION; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; UPREGULATION; WEIGHT REDUCTION;

EID: 84963799806     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.115.224105     Document Type: Article

References (44)

1. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-61.
2. Fernández-Galilea M, Prieto-Hontoria PL, Martínez JA, Moreno-Aliaga MJ. Antiobesity effects of a-lipoic acid supplementation. Clin Lipidol 2013;8:371-83.
3. Lorente-Cebrián S, Costa AG, Navas-Carretero S, Zabala M, Martínez JA, Moreno-Aliaga MJ. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. J Physiol Biochem 2013;69:633-51.
4. Carbonelli MG, Renzo LD, Bigioni M, Daniele ND, Lorenzo AD, Fusco MA. Alpha-lipoic acid supplementation: a tool for obesity therapy? Curr Pharm Des 2010;16:840-6.
5. Yu S, Zhang Y, Li M-Z, Xu H, Wang Q, Song J, Lin P, Zhang L, Liu Q, Huang QX, et al. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chin Med J (Engl) 2012;125:3440-4.
6. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8.
7. Yamada H, Yoshida M, Nakano Y, Suganami T, Satoh N, Mita T, Azuma K, Itoh M, Yamamoto Y, Kamei Y, et al. In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler Thromb Vasc Biol 2008;28:2173-9.
8. Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006;9:95-104.
9. Phang M, Lincz LF, Garg ML. Eicosapentaenoic and docosahexaenoic acid supplementations reduce platelet aggregation and hemostatic markers differentially in men and women. J Nutr 2013;143:457-63.
10. Satoh-Asahara N, Shimatsu A, Sasaki Y, Nakaoka H, Himeno A, Tochiya M, Kono S, Takaya T, Ono K, Wada H, et al. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care 2012;35:2631-9.
11. Huerta AE, Navas-Carretero S, Prieto-Hontoria PL, Martínez JA, Moreno-Aliaga MJ. Effects of a-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss. Obesity (Silver Spring) 2015;23:313-21.
12. Huerta AE, Prieto-Hontoria PL, Fernández-Galilea M, Sáinz N, Cuervo M, Martínez JA, Moreno-Aliaga MJ. Circulating irisin and glucose metabolism in overweight/obese women: effects of a-lipoic acid and eicosapentaenoic acid. J Physiol Biochem 2015;71:547-58.
13. World Health Organization. Global status report on noncommunicable diseases 2010. 1st Edition. Rome, Italy. World Health Organization; 2011.
14. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
15. Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, Martínez-Abundis E, Ramos-Zavala MG, Hernández-González SO, Jacques-Camarena O, Rodríguez-Morán M. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab 2010;95:3347-51.
16. Rendo-Urteaga T, García-Calzón S, González-Muniesa P, Milagro FI, Chueca M, Oyarzabal M, Azcona-Sanjulián MC, Martínez JA, Marti A. Peripheral blood mononuclear cell gene expression profile in obese boys who followed a moderate energy-restricted diet: differences between high and low responders at baseline and after the intervention. Br J Nutr 2015;113:331-42.
17. Samocha-Bonet D, Justo D, Rogowski O, Saar N, Abu-Abeid S, Shenkerman G, Shapira I, Berliner S, Tomer A. Platelet counts and platelet activation markers in obese subjects. Mediators Inflamm 2008; 2008:e834153.
18. Zhang Y, Han P, Wu N, He B, Lu Y, Li S, Liu Y, Zhao S, Liu L, Li Y. Amelioration of lipid abnormalities by alpha-lipoic acid through antioxidative and anti-inflammatory effects. Obesity (Silver Spring) 2011;19:1647-53.
19. Mollo R, Zaccardi F, Scalone G, Scavone G, Rizzo P, Navarese EP, Manto A, Pitocco D, Lanza GA, Ghirlanda G, et al. Effect of alphalipoic acid on platelet reactivity in type 1 diabetic patients. Diabetes Care 2012;35:196-7.
20. Manning PJ, Sutherland WH, Williams SM, Walker RJ, Berry EA, De Jong SA, Ryalls AR. The effect of lipoic acid and vitamin E therapies in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2013;23:543-9.
21. McNeilly AM, Davison GW, Murphy MH, Nadeem N, Trinick T, Duly E, Novials A, McEneny J. Effect of alpha-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance. Lipids Health Dis 2011;10:217.
22. Farhangi MA, Keshavarz S-A, Eshraghian M, Ostadrahimi A, Saboor-Yaraghi A-A. White blood cell count in women: relation to inflammatory biomarkers, haematological profiles, visceral adiposity, and other cardiovascular risk factors. J Health Popul Nutr 2013;31:58-64.
23. Oda E. High-sensitivity C-reactive protein and white blood cell count equally predict development of the metabolic syndrome in a Japanese health screening population. Acta Diabetol 2013;50:633-8.
24. Kao PC, Shiesh S-C, Wu T-J. Serum C-reactive protein as a marker for wellness assessment. Ann Clin Lab Sci 2006;36:163-9.
25. Coffman E, Richmond-Bryant J. Multiple biomarker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study. Popul Health Metr 2015;13:7.
26. Tamakoshi K, Toyoshima H, Yatsuya H, Matsushita K, Okamura T, Hayakawa T, Okayama A, Ueshima H., NIPPON DATA90 Research Group. White blood cell count and risk of all-cause and cardiovascular mortality in nationwide sample of Japanese. Circ J 2007;71:479-85.
27. Zhou Y, Wang Y, Qiao S. Apelin: a potential marker of coronary artery stenosis and atherosclerotic plaque stability in ACS patients. Int Heart J 2014;55:204-12.
28. Lv D, Li H, Chen L. Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis. Acta Biochim Biophys Sin (Shanghai) 2013;45:527-33.
29. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, Johnston NR, Denvir MA, Megson IL, Flapan AD, et al. Acute cardiovascular effects of apelin in humans potential role in patients with chronic heart failure. Circulation 2010;121:1818-27.
30. Castan-Laurell I, Dray C, Knauf C, Kunduzova O, Valet P. Apelin, a promising target for type 2 diabetes treatment? Trends Endocrinol Metab 2012;23:234-41.
31. Kadoglou NP, Tsanikidis H, Kapelouzou A, Vrabas I, Vitta I, Karayannacos PE, Liapis CD, Sailer N. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 2010;59:373-9.
32. Castan-Laurell I, Boucher J, Dray C, Daviaud D, Guigné C, Valet P. Apelin, a novel adipokine over-produced in obesity: friend or foe? Mol Cell Endocrinol 2005;245:7-9.
33. Lee WJ, Kim S-H, Kim GH, Han SM, Won JC, Jung CH, Park HS. Choi do S, Lee KU, Park JY. a-Lipoic acid activates dimethylarginine dimethylaminohydrolase in cultured endothelial cells. Biochem Biophys Res Commun 2010;398:653-8. Corrected and republished from: Biochem Biophys Res Commun 2010;401:491.
34. Mittermayer F, Pleiner J, Francesconi M, Wolzt M. Treatment with a-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus. Transl Res 2010;155:6-9.
35. Kohashi K, Nakagomi A, Saiki Y, Morisawa T, Kosugi M, Kusama Y, Atarashi H, Shimizu W. Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. J Atheroscler Thromb 2014;21:712-29.
36. Moreno-Aliaga MJ, Lorente-Cebrián S, Martínez JA. Regulation of adipokine secretion by n-3 fatty acids. Proc Nutr Soc 2010;69:324-32.
37. Pérez-Matute P, Pérez-Echarri N, Martínez JA, Marti A, Moreno-Aliaga MJ. Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: role of apoptosis, adiponectin and tumour necrosis factor-alpha. Br J Nutr 2007;97:389-98.
38. Pérez-Echarri N, Pérez-Matute P, Marcos-Gómez B, Baena MJ, Marti A, Martínez JA, Moreno-Aliaga MJ. Differential inflammatory status in rats susceptible or resistant to diet-induced obesity: effects of EPA ethyl ester treatment. Eur J Nutr 2008;47:380-6.
39. LeMieux MJ, Kalupahana NS, Scoggin S, Moustaid-Moussa N. Eicosapentaenoic acid reduces adipocyte hypertrophy and inflammation in diet-induced obese mice in an adiposity-independent manner. J Nutr 2015;145:411-7.
40. Itariu BK, Zeyda M, Hochbrugger EE, Neuhofer A, Prager G, Schindler K, Bohdjalian A, Mascher D, Vangala S, Schranz M, et al. Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am J Clin Nutr 2012;96:1137-49.
41. Liew C-C, Ma J, Tang H-C, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 2006;147:126-32.
42. Hermsdorff HH, Puchau B, Zulet MÁ, Martínez JA. Association of body fat distribution with proinflammatory gene expression in peripheral blood mononuclear cells from young adult subjects. OMICS 2010;14:297-307.
43. Oliver P, Reynés B, Caimari A, Palou A. Peripheral blood mononuclear cells: a potential source of homeostatic imbalance markers associated with obesity development. Pflugers Arch 2013;465:459-68.
44. Rodríguez-Pacheco F, García-Serrano S, García-Escobar E, Gutiérrez-Repiso C, García-Arnes J, Valdes S, Gonzalo M, Soriguer F, Moreno-Ruiz FJ, Rodriguez-Cañete A, et al. Effects of obesity/fatty acids on the expression of GPR120. Mol Nutr Food Res 2014;58:1852-60.